NEURODISCOVERY: NSL-101 'EFFECTIVE IN PAIN RELIEF’
August 27th 2008 12:34
Tuesday August 26, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: VENTRACOR UP 14%, STEM CELL DOWN 21%
* NEURODISCOVERY: ‘TRIAL SHOWS NSL-101 EFFECTIVE IN PAIN RELIEF’
* AVEXA TAKES GREATER CONTROL OF LEAD DRUG APRICITABINE
* MONASH UNI’S ‘NANO-TROJAN-HORSE’ TO AID NUTRITION
* MEDICAL THERAPIES’ CSO, DIRECTOR RESIGNS; US PATENT GRANTED
* BIOPROSPECT BIOEFFECTIVE CHOOK TRIAL ‘NOT SIGNIFICANT’
* FOUR WOMEN SCIENTISTS WIN $20K L’ORÉAL FELLOWSHIPS
* BIO-MELBOURNE NETWORK: MANAGING A MULTI-PRODUCT PIPELINE
* ANTISENSE EGM BACKS SHARE ISSUE, DIRECTORS’ OPTIONS
* VICTORIA COLLEGE OF PHARMACY BECOMES MONASH FACULTY
* AUSBIOTECH’S AUGUST BIO-BEERS
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
NEURODISCOVERY
Neurodiscovery says one its two phase IIa clinical trials has shown NSL-101 to be equivalent to commercially available anaesthetic for dental surgery.
Neurodiscovery said NSL-101 “was highly effective in the treatment of pain associated with root planing and scaling, a painful procedure used to combat periodontitis”.
A parallel clinical trial for the treatment of post-operative pain caused by the extraction of impacted third molars or ‘wisdom teeth’ was unable to clearly demonstrate NSL-101’s effects due to unexpected confounding factors.
This study was unable to evaluate the analgesic efficacy of NSL-101 compared with placebo in patients after the extraction of one or more impacted wisdom teeth.
Neurodiscovery said the duration of the local anaesthetic used during surgery was longer than expected, “thus potentially masking any analgesic effects of NSL-101 and compromising the outcome of the study”.
Neurodiscovery said the second study was designed to ensure that patients would not experience severe pain at any time and the company said NSL-101 was found to be well tolerated.
The first study was a double-blind, randomized controlled trial evaluating the analgesic efficacy, anti-inflammatory activity and safety of NSL-101 gel compared with a 5% local anaesthetic in a periodontological procedure of scaling and root planning.
Neurodiscovery said no adverse events attributed to the use of NSL-101 or anaesthetic gel were reported and NSL-101 produced numerically superior analgesia compared to 5% anaesthetic gel, but the difference was not statistically significant.
Neurodiscovery said the periodontitis study compared the analgesic efficacy and safety of NSL-101 gel with a local anaesthetic, which is the gold standard for pain prevention during scaling and root planning.
This procedure was used to treat moderate to severe periodontitis and was typically associated with significant pain.
The company said NSL-101 was highly effective and well tolerated.
“It was found to be equally effective as the local anaesthetic gel and no adverse effects were reported,” Neurodiscovery said.
Neurodiscovery said the results from the periodontitis trial demonstrated that NSL-101 was an effective analgesic preparation and this proof-of-concept data “significantly enhances the value of this clinical asset”.
The company said the results had led to a patent filing describing the preparation, formulation and use of NSL-101.
Neurodiscovery said it was seeking an appropriate out-licencing and/or collaborative partner who would receive the rights to market NSL-101.
Neurodiscovery chairman Dr Mark Treherne said that there were “significant commercial opportunities for new additions to toothpastes, ulcer gels, toothache remedies, as well as creams and ointments for stings and grazes”.
“NSL-101 may also have future commercial applications following minor cosmetic procedures,” Dr Treherne said.
The trial of 50 patients aged 18-55 years with moderate to severe periodontitis undergoing scaling and root planning procedure was conducted at Cayetano Heredia University in Lima, Peru.
Neurodiscovery fell one cent or 10 percent to nine cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 31 |
| Vote |
Add To: 
subscribe to this blog